You are viewing Allergic Living United States | Switch to Canada
Allergies, Asthma & Gluten-free

SIGN UP For Our Free e-Newsletter

Submit
Click To See Past Newsletters
Recalls

Auvi-Q and Allerject Recall: Late 2015 Update

adult-children-injectionBoth child and adult Auvi-Q auto-injectors have been recalled.

Dec. 2: Read the latest Sanofi Canada update on the Allerject recall here.

Read more about the Sanofi US recall of Auvi-Q here.

In late October, following the recall of all Auvi-Q epinephrine auto-injectors in the U.S., and all Allerject auto-injectors in Canada, the device’s manufacturer, Sanofi US, said it was “temporarily ceasing” production of Auvi-Qs and Allerjects.

Both the 0.15 mg (child) and 0.3 mg (adult) strengths of the devices have been recalled. The company said that some units were found to potentially have inaccurate dosage delivery.

Sanofi US said it received 26 reports of suspected device malfunctions in the U.S. and Canada, as of Oct. 26, 2015. The company has yet to report the results of its investigation. Dr. Paul Chew, chief medical officer for Sanofi US, told Allergic Living in an  interview that “the first thing that we need to do is fully understand what the issue behind this potential inaccurate dosage delivery is. Then I think we’ll be able to comment better.”

The recall of the Auvi-Q and Allerject devices remains in effect. If you live in the U.S., click here for more information about how to receive a full refund for replacing your Auvi-Q with another auto-injector, such as the EpiPen or the Adrenaclick.

20151028_C6278_PHOTO_EN_531746Pfizer Canada now says it has sufficient supplies to replace all Allerjects in Canada with EpiPens.

If you live in Canada, click here for more information about the Allerject recall. There were supply shortages of replacement EpiPens in some Canadian provinces in the first two weeks of the recall, so many pharmacies limited sales to one auto-injector per patient. Pfizer Canada, which distributes the device, told Allergic Living that new shipments from the U.S. were expected by the end of last week.

“Based on the intelligence that we have received from many of our customers, we feel that the EpiPen supply has been normalized on the Canadian market,” said spokesperson Manon Genin. “We feel that these new quantities arriving at our distribution facility in Canada are sufficient to meet demand for the foreseeable future. As of the week of November 23, we will be in a position to replenish all the recalled Allerject devices.”

To give us feedback on this article, please email comments@allergicliving.com

Close Close Free E-Letters From Allergic Living Free E-Letters From Allergic LivingFree E-Letters From Allergic Living